Scholarlink

Aim <p>To assess the real-world use, glycemic outcomes, and patient experience of a new two-in-one insulin pump (with switchable tubeless patch-on and tubed portable forms, available with standard or short cannulas) in Chinese adults with type 1 diabetes (T1D). Methods: This study was based on a multicenter survey in China. By the end of December 2025, 47 T1D patients had been treated with the Ari two-in-one insulin pump for at least 3 months. The questionnaire covered blood glucose management, quality of life (QoL), product experience, and patients’ future expectations. All data were self-reported and analyzed using descriptive statistics. Results: The mean HbA1c level in the month before the survey was 7.2 ± 1.4%. The sensor-derived glucose metrics: time in range (TIR, 3.9–10.0 mmol/L) was 74.0 ± 14.1%, time above range (TAR, &gt; 10.0 mmol/L) was 17.9 ± 4.9%, and time below range (TBR, &lt; 3.9 mmol/L) was 8.1 ± 2.8%. All of the mentioned values were within clinical targets except that TBR did not reach the clinical goal for hypoglycemia. Compared with the period before pump therapy, 55.3% and 53.2% of patients reported a reduction in the frequency of hypoglycemic and hyperglycemic episodes, respectively. Regarding QoL, 48.9% of the patients reported feeling confident in their treatment and freedom in their daily activities, 78.7% reported better wearing comfort, and 76.6% experienced effective improvement in their overall QoL. In terms of product experience, the distribution of the form of usage of the pump was: 15 cases (31.9%) used the portable (tubed) form, 14 cases (29.8%) used the patch (tubeless) form, and 18 cases (38.3%) had experience with both forms.Among the latter group, satisfaction levels were highest for device safety alerts, operating system, operational stability, and overall design. Regarding future technologies, over half of the patients were not sufficiently aware of hybrid closed-loop pumps. Their core functional demands consisted of two types of intelligent modules: (1) automatic insulin delivery adjustment, and (2) integration with continuous glucose monitoring (CGM). Conclusion: This first cross-sectional patient survey in China showed that the new two-in-one insulin pump was associated with good glycemic control (TIR 74%) and improved QoL. This highly switchable design is innovative as it directly addresses the major issue of skin health in long-term pump therapy and offers great flexibility. Future development should progress toward an automated closed-loop system.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Insulin pump therapy for T1D: a real-world analysis of a novel two-in-one insulin pump in Chinese adults with type 1 diabetes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月23日

查看全文
  • Yan Lü,
  • Ziyi Li,
  • Yang Yang,
  • Xiaofen Lian,
  • Shaoqing Shi,
  • Fan Zhang

摘要

Aim

To assess the real-world use, glycemic outcomes, and patient experience of a new two-in-one insulin pump (with switchable tubeless patch-on and tubed portable forms, available with standard or short cannulas) in Chinese adults with type 1 diabetes (T1D). Methods: This study was based on a multicenter survey in China. By the end of December 2025, 47 T1D patients had been treated with the Ari two-in-one insulin pump for at least 3 months. The questionnaire covered blood glucose management, quality of life (QoL), product experience, and patients’ future expectations. All data were self-reported and analyzed using descriptive statistics. Results: The mean HbA1c level in the month before the survey was 7.2 ± 1.4%. The sensor-derived glucose metrics: time in range (TIR, 3.9–10.0 mmol/L) was 74.0 ± 14.1%, time above range (TAR, > 10.0 mmol/L) was 17.9 ± 4.9%, and time below range (TBR, < 3.9 mmol/L) was 8.1 ± 2.8%. All of the mentioned values were within clinical targets except that TBR did not reach the clinical goal for hypoglycemia. Compared with the period before pump therapy, 55.3% and 53.2% of patients reported a reduction in the frequency of hypoglycemic and hyperglycemic episodes, respectively. Regarding QoL, 48.9% of the patients reported feeling confident in their treatment and freedom in their daily activities, 78.7% reported better wearing comfort, and 76.6% experienced effective improvement in their overall QoL. In terms of product experience, the distribution of the form of usage of the pump was: 15 cases (31.9%) used the portable (tubed) form, 14 cases (29.8%) used the patch (tubeless) form, and 18 cases (38.3%) had experience with both forms.Among the latter group, satisfaction levels were highest for device safety alerts, operating system, operational stability, and overall design. Regarding future technologies, over half of the patients were not sufficiently aware of hybrid closed-loop pumps. Their core functional demands consisted of two types of intelligent modules: (1) automatic insulin delivery adjustment, and (2) integration with continuous glucose monitoring (CGM). Conclusion: This first cross-sectional patient survey in China showed that the new two-in-one insulin pump was associated with good glycemic control (TIR 74%) and improved QoL. This highly switchable design is innovative as it directly addresses the major issue of skin health in long-term pump therapy and offers great flexibility. Future development should progress toward an automated closed-loop system.